Vivus hopes weight-loss app will fatten up Qsymia sales

Weight-loss apps have become popular, so why not a weight-loss app for a weight-loss drug? Qsymia maker Vivus figures it is worth a try. The company ($VVUS), which has found the uptake slow on its highly vaunted drug, last week launched a mobile version of the weight-loss support tools already on its website, Medical Marketing & Media reports. The app, which works on Android and Apple products, has a diary, so users can note everything they eat and get informational emails rolled out periodically to give them ideas on how to lose weight over a year's time. Report

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.